iPSCs engrafted in allogeneic hosts without immunosuppression induce donor-specific tolerance to secondary allografts

T Tomoki Kamatani (Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University) R Reiko Kimura (Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University) S Satoshi Ikeda (Sumitomo Pharma, Co., Ltd.) M Makoto Inoue K Ken-ichiro Seino (Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University)

Abstract

Currently, most cell or tissue transplantations using induced pluripotent stem cells (iPSCs) are anticipated to involve allogeneic iPSCs. However, the immunological properties of iPSCs in an allogeneic setting are not well understood. We previously established a mouse transplantation model of MHC-compatible/minor antigen-mismatched combinations, assuming a hypoimmunogenic iPSC-setting. Here, we found that iPSCs subcutaneously inoculated into MHC-compatible allogeneic host mice resisted rejection and formed teratomas without immunosuppressant administration. Notably, when skin grafts were transplanted onto hosts more than 40 d after the initial iPSCs inoculation, only the skin of the same strain as the initial iPSCs was engrafted. Therefore, donor-specific immune tolerance was induced by a single iPSC inoculation. Diverse analyses, including single-cell RNA-sequencing after transplantation, revealed an increase in regulatory T cell (Treg) population, particularly CD25 + CD103 + effector Tregs within the teratoma and skin grafts. The removal of CD25 + or Foxp3 + cells suppressed the increase in effector Tregs and disrupted graft acceptance, indicating the importance of these cells in the establishment of immune tolerance. Within the teratoma, we observed an increase in TGF-β2 levels, suggesting an association with the increase in effector Tregs. Our results provide important insights for future applications of allogeneic iPSC-based cell or tissue transplantation.

Article Details

Volume / Issue Vol. 122, Issue 11
Published March 18, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (5)

T

Tomoki Kamatani

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University

R

Reiko Kimura

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University

S

Satoshi Ikeda

Sumitomo Pharma, Co., Ltd.

M

Makoto Inoue

K

Ken-ichiro Seino

Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University